STANDARD BIOTOOLS INC. (LAB): M&A transaction — Standard BioTools completes SomaLogic sale to Illumina for up to $425M; holds ~$550M cash

STANDARD BIOTOOLS INC.

Received $350M upfront cash at closing; eligible for up to $75M in earnout payments based on 2025-2026 revenue targets.
Post-close cash and equivalents estimated at ~$550M, excluding potential earnouts, to fund inorganic growth.
Retained mass cytometry and microfluidics businesses; continuing operations on track for positive adjusted EBITDA in 2026.
Company to receive 2% royalty on SOMAmer-based NGS kit sales for 10 years and a co-exclusive license for singleplex assays.
Transaction marks strategic exit from aptamer/proteomics business; management plans disciplined M&A to accelerate growth.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

STANDARD BIOTOOLS INC. completed a disposition involving Illumina, Inc. for $350 million in upfront cash and up to $75 million in earnout payments for aggregate cash consideration of up to $425 million (closed 2026-01-30).

Action: disposition
Counterparty: Illumina, Inc.
Consideration: $350 million in upfront cash and up to $75 million in earnout payments for aggregate cash consideration of up to $425 million
Closing: 2026-01-30

Exact text from the filing

which are being retained by the Company. Under the terms of the Purchase Agreement, Purchaser acquired the Shares for aggregate cash consideration of up to $425 million, comprising (i) an upfront payment of $350 million in cash, which was paid at the closing of the Transaction, as adjusted in accordance with the terms of the Purchase Agreement

View on SEC.gov

Browse all m&a transactions →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-008375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.